ORAGENICS, INC. Proceeds from Warrant Exercises
ORAGENICS, INC. (OGEN) reported Proceeds from Warrant Exercises of $2.26 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-04-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2023-04-17
- ORAGENICS, INC. proceeds from warrant exercises for the quarter ending 2021-12-31 was $1.00, a 0.00% change year-over-year.
- ORAGENICS, INC. proceeds from warrant exercises for the quarter ending 2021-09-30 was $0.00.
- ORAGENICS, INC. proceeds from warrant exercises for the quarter ending 2021-06-30 was $0.00.
- ORAGENICS, INC. proceeds from warrant exercises for the quarter ending 2021-03-31 was $2.26M.
- ORAGENICS, INC. proceeds from warrant exercises for fiscal 2021 was $2.26M, a 56.37% decline from fiscal 2020.
- ORAGENICS, INC. proceeds from warrant exercises for fiscal 2020 was $5.18M.
| Period end | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-04-17 | $1.00 derived: sum of 2 quarters · filed 2023-04-17 | $1.00 derived: sum of 3 quarters · filed 2023-04-17 | $2.26M 10-K · filed 2023-04-17 |
| 2021-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2023-04-14 | $0.00 derived: sum of 2 quarters · filed 2023-04-14 | $2.26M 10-Q/A · filed 2023-04-14 | $2.26M derived: sum of 4 quarters · filed 2023-04-14 |
| 2021-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2023-04-14 | $2.26M 10-Q/A · filed 2023-04-14 | $2.26M derived: sum of 3 quarters · filed 2023-04-14 | |
| 2021-03-31 | $2.26M 10-Q/A · filed 2023-04-14 | $2.26M derived: sum of 2 quarters · filed 2023-04-14 | ||
| 2020-12-31 | $1.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-29 | $5.18M 10-K/A · filed 2022-07-29 | ||
| 2020-09-30 | $5.18M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |